Diabetic Gastroparesis Pipeline Review - H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Diabetic Gastroparesis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.


This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2020, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 3, 6 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Diabetic Gastroparesis - Overview
  • Diabetic Gastroparesis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Diabetic Gastroparesis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diabetic Gastroparesis - Companies Involved in Therapeutics Development
  • AlfaSigma SpA
  • Allergan Plc
  • Atlantic Healthcare Plc
  • Bird Rock Bio Inc
  • Censa Pharmaceuticals Inc
  • CinRx Pharma LLC
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Vanda Pharmaceuticals Inc
  • Diabetic Gastroparesis - Drug Profiles
  • CIN-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CNSA-001 - Drug Profile
  • ETX-101 - Drug Profile
  • metoclopramide - Drug Profile
  • nimacimab - Drug Profile
  • prucalopride succinate - Drug Profile
  • relamorelin - Drug Profile
  • renzapride - Drug Profile
  • TAK-906 - Drug Profile
  • tradipitant - Drug Profile
  • velusetrag - Drug Profile
  • Diabetic Gastroparesis - Dormant Projects
  • Diabetic Gastroparesis - Discontinued Products
  • Diabetic Gastroparesis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/o3xhye


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900